Pulsesight
  • About us
    • About us
    • Team
    • Investors
  • Technology
  • Pipeline
    • Pipeline
    • About AMD
    • PST-611
    • PST-809
  • News & Events
    • Press Releases
    • Events
    • In the News
  • Contact

Month: April 2024

PulseSight Therapeutics Establishes International Scientific and Clinical Advisory Board

Posted on April 9, 2024January 18, 2026 by edgover
PulseSight Therapeutics Establishes International Scientific and Clinical Advisory Board
Posted in In the news

Recent Posts

  • EarlySight and PulseSight Therapeutics collaborate to add Cellularis® 2 Retinal Imaging to PST-611 Phase 2 Study
  • PulseSight’s PST-611 Shows 35-52% Slowing of Retinal Cell Loss Biomarkers in Phase I Geographic Atrophy Trial
  • New PST-611 Data Suggest Slower GA Progression
  • PulseSight Reports Favorable Safety and Early Efficacy Signals for PST-611 in Geographic Atrophy
  • PulseSight presents PST-611 Phase I new early clinical efficacy data at EURETINA, offering a potential breakthrough approach to treat Dry AMD/Geographic Atrophy

Recent Comments

No comments to show.

Archives

  • October 2026
  • September 2026
  • August 2026
  • May 2026
  • April 2026
  • January 2026
  • October 2025
  • September 2025
  • August 2025
  • July 2025
  • June 2025
  • May 2025
  • April 2025
  • February 2025
  • January 2025
  • November 2024
  • October 2024
  • September 2024
  • August 2024
  • April 2024
  • March 2024
  • February 2024

Categories

  • In the news
  • Press release
CONTACT US
PRIVACY POLICY
DISCLAIMER

© 2026 PULSESIGHT THERAPEUTICS ALL RIGHTS RESERVED